Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Soliris
Pharma
Argenx's Vyvgart holds its own against AZ's rare disease duo
For 2024’s second quarter, infused Vyvgart and its subcutaneous sibling Vyvgart Hytrulo brought home $478 million in sales.
Fraiser Kansteiner
Jul 25, 2024 3:16pm
Amgen grabs FDA thumbs-up for Soliris biosim, eyes 2025 launch
May 29, 2024 10:26am
AstraZeneca's rare disease add-on therapy Voydeya scores FDA nod
Apr 1, 2024 11:48am
Roche's answer to AstraZeneca PNH drugs nabs China nod
Feb 8, 2024 11:02am
Novartis gains first FDA approval for touted blood disorder drug
Dec 6, 2023 11:02am
Alexion inks $125M deal to resolve investor lawsuit
Sep 14, 2023 11:41am
